Goldman Sachs’s Centessa Pharmaceuticals CNTA Stock Holding History

Goldman Sachs’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37,000	Closed	-$486K	–	6374
2025 Q2	$486K	Buy	37,000 +7,000	+23%	+$88.7K	﹤0.01%	5179
2025 Q1	$431K	Buy	+30,000	New	+$491K	﹤0.01%	5272

Goldman Sachs's CNTA Position: Q2 2026 in Review

Goldman Sachs sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,144,560 shares — an estimated $45.5M sold.

Goldman Sachs first reported a position in CNTA in Q2 2022 and held it in 15 quarters. The position peaked at $45.5M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Goldman Sachs reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 1,144,560 Centessa Pharmaceuticals shares in Q2 2026, an estimated $45.5M.
Goldman Sachs first reported a position in Centessa Pharmaceuticals in Q2 2022 and held it in 15 quarters.
Goldman Sachs's Centessa Pharmaceuticals position peaked at $45.5M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.